We are live on ! Find out more
BLRX

BioLineRX
BLRX

21 hedge funds and large institutions have $17M invested in BioLineRX in 2015 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

5% more funds holding

Funds holding: 20 → 21 (+1)

42% less capital invested

Capital invested by funds: $29.3M → $17M (-$12.3M)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

Holders
21
Holders Change
+1
Holders Change %
+5%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$711K
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$98.2K
3
AL
Airain Ltd
Guernsey
+$35.2K
4
Jane Street
Jane Street
New York
+$32K
5
Millennium Management
Millennium Management
New York
+$30.9K

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$217K
2
O
OrbiMed
New York
-$172K
3
VKH
Virtu KCG Holdings
New York
-$154K
4
NCCM
Nine Chapters Capital Management
New Jersey
-$125K
5
SM
Senvest Management
New York
-$120K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Senvest Management
New York
$5.48M -$120K -112 -2%
BC
2
Broadfin Capital
New York
$5.36M +$711K +666 +13%
O
3
OrbiMed
New York
$1.59M -$172K -161 -9%
Alyeska Investment Group
4
Alyeska Investment Group
Illinois
$1.21M +$98.2K +92 +7%
Millennium Management
5
Millennium Management
New York
$918K +$30.9K +29 +3%
Morgan Stanley
6
Morgan Stanley
New York
$812K -$32K -30 -3%
Deutsche Bank
7
Deutsche Bank
Germany
$802K -$217K -203 -19%
OM
8
Opaleye Management
Massachusetts
$383K – – –
NCCM
9
Nine Chapters Capital Management
New Jersey
$92K -$125K -117 -54%
BCA
10
Benchmark Capital Advisors
New York
$72K -$47K -44 -36%
MC
11
Menta Capital
California
$71K -$29.9K -28 -26%
NFG
12
Next Financial Group
Texas
$57K – – –
Bank of New York Mellon
13
Bank of New York Mellon
New York
$30K +$3.2K +3 +10%
AL
14
Airain Ltd
Guernsey
$30K +$35.2K +33 New
Jane Street
15
Jane Street
New York
$28K +$32K +30 New
CCB
16
Cutter & Co Brokerage
Missouri
$19K – – –
PNC Financial Services Group
17
PNC Financial Services Group
Pennsylvania
$15K – – –
UBS Group
18
UBS Group
Switzerland
$6K +$6.4K +6 New
Royal Bank of Canada
19
Royal Bank of Canada
Ontario, Canada
$5K – – –
Wells Fargo
20
Wells Fargo
California
$2K – – –
KF
21
Krilogy Financial
Missouri
$2K +$2.13K +2 New
VKH
22
Virtu KCG Holdings
New York
– -$154K -97 Closed
RCM
23
Rotella Capital Management
Washington
– -$36K -23 Closed
Nomura Holdings
24
Nomura Holdings
Japan
– -$23K -18 Closed

BLRX Hedge Fund Activity: Q3 2015 in Review

21 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2015, worth a combined $17M — down 42% from $29.3M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BLRX positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 7 trimmed.

The largest buyer was Broadfin Capital, adding an estimated $711K. The largest seller was Deutsche Bank, cutting an estimated $217K.

  • 21 institutional investors held BioLineRX (BLRX) as of Q3 2015, up from 20 in Q2 2015.
  • Funds reported $17M of BioLineRX stock for Q3 2015, down 42% quarter-over-quarter.
  • 4 funds opened new BioLineRX positions in Q3 2015 and 3 closed out, a net change of +1 holder.
  • The largest BioLineRX buyer in Q3 2015 was Broadfin Capital, an estimated $711K added.
  • The largest BioLineRX seller in Q3 2015 was Deutsche Bank, an estimated $217K sold.

Based on aggregated 13F filings for Q3 2015.